Hepato Pancreato Biliary

Journal

Publication Venue For

  • Beyond insurance status: the impact of Medicaid expansion on the diagnosis of Hepatocellular Carcinoma.  24:1271-1279. 2022
  • The impact of upper gastrointestinal surgical volume on short term pancreaticoduodenectomy outcomes for pancreatic adenocarcinoma in the SEER-Medicare population.  24:868-874. 2022
  • Diagnosis and treatment of pancreatic duct disruption or disconnection: an international expert survey and case vignette study.  23:1201-1208. 2021
  • The role of racial segregation in treatment and outcomes among patients with hepatocellular carcinoma.  23:854-860. 2021
  • A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry.  21:1024-1031. 2019
  • Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma.  21:379-386. 2019
  • Trans-arterial chemoembolization of hepatocellular carcinoma is efficacious, regardless of hospital characteristics or TACE volume.  19:s123. 2017
  • Pancreas fistula risk prediction: implications for hospital costs and payments.  19:140-146. 2017
  • Impact of adjuvant chemoradiation on survival in patients with resectable cholangiocarcinoma.  18:843-850. 2016
  • Diagnostic strategy and timing of intervention in infected necrotizing pancreatitis: an international expert survey and case vignette study.  18:49-56. 2016
  • Distal pancreatectomy with celiac axis resection: What are the added risks?.  17:777-784. 2015
  • Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥3 cm.  17:140-149. 2015
  • Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma..  16:1095-1101. 2014
  • Chemoembolization outcomes for hepatocellular carcinoma in cirrhotic patients with compromised liver function.  16:648-655. 2014
  • Computed tomography predictors of hepatocellular carcinoma tumour necrosis after chemoembolization.  16:327-335. 2014
  • Defining the post-operative morbidity index for distal pancreatectomy.  16:915-923. 2014
  • Prophylactic octreotide for pancreatoduodenectomy: More harm than good?.  16:954-962. 2014
  • Rankings versus reality in pancreatic cancer surgery: A real-world comparison.  16:528-533. 2014
  • Assessing the impact of a fistula after a pancreaticoduodenectomy using the Post-operative Morbidity Index.  15:781-788. 2013
  • Computed tomography attenuation and patient characteristics as predictors of complications after pancreaticoduodenectomy.  15:709-715. 2013
  • Factors associated with delayed gastric emptying after pancreaticoduodenectomy.  15:763-772. 2013
  • Equivalent survival following liver transplantation in patients with non-alcoholic steatohepatitis compared with patients with other liver diseases.  14:625-634. 2012
  • Effect of centre volume and high donor risk index on liver allograft survival.  13:447-453. 2011
  • Profile of health-related quality of life outcomes after liver transplantation: Univariate effects and multivariate models.  10:30-37. 2008
  • What affects mortality after the operative management of hepatic abscess?.  8:175-178. 2006
  • Pancreatic somatostatinoma associated with obstructive jaundice, pancreatic and biliary Kaposi's sarcoma in a man with neurofibromatosis.  5:49-53. 2003
  • International Standard Serial Number (issn)

  • 1365-182X
  • Electronic International Standard Serial Number (eissn)

  • 1477-2574